Hans-Georg Rammensee

List of Publications by Year
in descending order

166 papers	16,478 citations	36303 51 h-index	16650 123 g-index
181 all docs	181 docs citations	181 times ranked	17082 citing authors

#	Article	IF	Citations
1	Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature, 1991, 351, 290-296.	27.8	2,407
2	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	27.8	1,705
3	MHC ligands and peptide motifs: first listing. Immunogenetics, 1995, 41, 178-228.	2.4	1,606
4	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 2012, 18, 1254-1261.	30.7	721
5	Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood, 2002, 99, 3916-3922.	1.4	660
6	In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature, 1989, 342, 561-564.	27.8	655
7	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
8	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nature Immunology, 2021, 22, 74-85.	14.5	490
9	Chemistry of peptides associated with MHC class I and class II molecules. Current Opinion in Immunology, 1995, 7, 85-96.	5.5	336
10	*In vivo* application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 2000, 30, 1-7.	2.9	331
11	Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis. Journal of Experimental Medicine, 2000, 191, 1965-1974.	8.5	325
12	The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. European Journal of Immunology, 2000, 30, 2211-2215.	2.9	287
13	Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Research, 2002, 62, 5818-27.	0.9	161
14	The peptide binding motif of the disease associated HLA-DQ (α 1* 0501, β 1* 0201) molecule. European Journal of Immunology, 1996, 26, 2764-2772.	2.9	154
15	A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 2022, 601, 617-622.	27.8	153
16	The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9942-E9951.	7.1	152
17	Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood, 2002, 99, 3830-3837.	1.4	151
18	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	7.1	150

#	Article	IF	Citations
19	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell, 2020, 183, 1264-1281.e20.	28.9	133
20	The Tï¿½bingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunology, Immunotherapy, 2004, 53, 187-195.	4.2	132
21	Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. European Journal of Immunology, 2000, 30, 2216-2225.	2.9	131
22	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine, 2021, 13, .	12.4	128
23	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
24	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nature Reviews Clinical Oncology, 2020, 17, 595-610.	27.6	124
25	Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface. Molecular and Cellular Proteomics, 2007, 6, 102-113.	3.8	121
26	Cutaneous Innate Immune Sensing of Toll-like Receptor 2-6 Ligands Suppresses T Cell Immunity by Inducing Myeloid-Derived Suppressor Cells. Immunity, 2014, 41, 762-775.	14.3	119
27	The SysteMHC Atlas project. Nucleic Acids Research, 2018, 46, D1237-D1247.	14.5	119
28	Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human VÎ³9/VÎ´2 T cells in tumor immunity. European Journal of Immunology, 1997, 27, 3368-3379.	2.9	115
29	The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. European Journal of Immunology, 1997, 27, 923-927.	2.9	111
30	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Medicine, 2019, 11, 28.	8.2	107
31	An open-source computational and data resource to analyze digital maps of immunopeptidomes. ELife, 2015, 4, .	6.0	107
32	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cellâ€"based immunotherapy. Blood, 2015, 126, 1203-1213.	1.4	103
33	Novel multiâ€peptide vaccination in Hlaâ€A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.	2.3	97
34	The Peptide Vaccine of the Future. Molecular and Cellular Proteomics, 2021, 20, 100022.	3.8	94
35	HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Review of Vaccines, 2013, 12, 1211-1217.	4.4	87
36	TLR9 independent interferon Î± production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Annals of the Rheumatic Diseases, 2014, 73, 2199-2207.	0.9	83

#	Article	IF	Citations
37	Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nature Biotechnology, 2004, 22, 450-454.	17.5	82
38	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological Reviews, 2017, 280, 165-174.	6.0	82
39	Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nature Communications, 2013, 4, 1616.	12.8	81
40	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. Journal of Immunology, 2017, 199, 2639-2651.	0.8	81
41	gp96—The immune system's Swiss army knife. Nature Immunology, 2000, 1, 100-101.	14.5	78
42	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. Journal of Hepatology, 2016, 65, 849-855.	3.7	75
43	Towards patient-specific tumor antigen selection for vaccination. Immunological Reviews, 2002, 188, 164-176.	6.0	73
44	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nature Communications, 2021, 12, 1152.	12.8	71
45	Promiscuous survivin peptide induces robust CD4[+] T‑cell responses in the majority of vaccinated cancer patients. International Journal of Cancer, 2012, 131, 140-149.	5.1	70
46	Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. European Journal of Immunology, 1998, 28, 4029-4036.	2.9	68
47	PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma. Cancer Immunology Research, 2019, 7, 1891-1899.	3.4	66
48	[64]Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1161-1166.	7.1	65
49	Identification of non-mutated neoantigens presented by TAP-deficient tumors. Journal of Experimental Medicine, 2018, 215, 2325-2337.	8.5	64
50	The regulatory landscape for actively personalized cancer immunotherapies. Nature Biotechnology, 2013, 31, 880-882.	17.5	62
51	An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. Journal of Immunological Methods, 2014, 405, 192-198.	1.4	59
52	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood, 2019, 133, 550-565.	1.4	57
53	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
54	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.9	56

#	Article	IF	Citations
55	A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology, 1998, 28, 3301-3311.	2.9	54
56	Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres. Journal of Immunology, 2003, 171, 4974-4978.	0.8	53
57	Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunology, Immunotherapy, 2007, 57, 175-183.	4.2	50
58	Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia. Molecular Therapy, 2015, 23, 648-655.	8.2	48
59	Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. International Journal of Cancer, 2000, 87, 399-404.	5.1	45
60	Dipeptides catalyze rapid peptide exchange on MHC class I molecules. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 202-207.	7.1	45
61	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
62	GÎ±s-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells. Journal of Experimental Medicine, 2019, 216, 517-526.	8.5	45
63	A tissue-based draft map of the murine MHC class I immunopeptidome. Scientific Data, 2018, 5, 180157.	5.3	45
64	Personalized cancer vaccines: adjuvants are important, too. Cancer Immunology, Immunotherapy, 2018, 67, 1911-1918.	4.2	44
65	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. OncoImmunology, 2018, 7, e1316438.	4.6	42
66	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. OncoImmunology, 2016, 5, e1108511.	4.6	41
67	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
68	HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain, 2013, 136, 1783-1798.	7.6	40
69	Human Peripheral CD4+ VÎ±Â´1+ Î³Î´T Cells Can Develop into Î±Î²T Cells. Frontiers in Immunology, 2014, 5, 645.	4.8	40
70	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028829.	5.5	40
71	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
72	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	7.6	39

#	Article	IF	Citations
73	Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. European Journal of Immunology, 1998, 28, 2432-2443.	2.9	38
74	NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 755.	12.8	38
75	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. Molecular Therapy - Oncolytics, 2019, 12, 147-161.	4.4	38
76	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
77	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight, 2019, 4, .	5.0	36
78	High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules. Science Immunology, 2019, 4, .	11.9	35
79	MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics. Journal of Proteome Research, 2019, 18, 3876-3884.	3.7	35
80	Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discovery, 2021, 11, 1982-1995.	9.4	34
81	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	8.2	32
82	Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. Journal of Proteome Research, 2021, 20, 289-304.	3.7	32
83	Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. Molecular and Cellular Proteomics, 2020, 19, 432-443.	3.8	31
84	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 2555-2566.	7.0	31
85	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Frontiers in Immunology, 2019, 10, 2526.	4.8	29
86	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1219825.	4.6	28
87	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
88	An IgG–based bispecific antibody for improved dual targeting in PSMA–positive cancer. EMBO Molecular Medicine, 2021, 13, e11902.	6.9	28
89	Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. Journal of General Virology, 2008, 89, 2090-2097.	2.9	27
90	Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. European Journal of Immunology, 1996, 26, 875-879.	2.9	25

#	Article	IF	Citations
91	Long-Term Immunity against Actual Poxviral HLA Ligands as Identified by Differential Stable Isotope Labeling. Journal of Immunology, 2008, 181, 6371-6383.	0.8	25
92	Innate immune system favors emergency monopoiesis at the expense of DCâ€differentiation to control systemic bacterial infection in mice. European Journal of Immunology, 2015, 45, 2821-2833.	2.9	24
93	Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response. Cancer Immunology, Immunotherapy, 2019, 68, 1949-1958.	4.2	24
94	Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-As. European Journal of Immunology, 2001, 31, 551-562.	2.9	23
95	Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1485-1497.	4.2	22
96	The European Regulatory Environment of RNA-Based Vaccines. Methods in Molecular Biology, 2017, 1499, 203-222.	0.9	22
97	Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. Vaccines, 2021, 9, 428.	4.4	22
98	Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2021, 12, 705974.	4.8	22
99	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. OncoImmunology, 2016, 5, e1204504.	4.6	19
100	Identification of Immunogenic Epitopes by MS/MS. Cancer Journal (Sudbury, Mass), 2017, 23, 102-107.	2.0	19
101	Activated integrins identify functional antigen-specific CD8[+]T cells within minutes after antigen stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5536-E5545.	7.1	19
102	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. Molecular Therapy, 2016, 24, 1634-1643.	8.2	18
103	HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. OncoImmunology, 2016, 5, e1065369.	4.6	18
104	HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation. Cancers, 2020, 12, 1835.	3.7	18
105	Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. , 1998, 75, 688-693.		17
106	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. European Urology Focus, 2019, 5, 604-607.	3.1	17
107	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2000-2000.	1.6	17
108	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS ONE, 2016, 11, e0167017.	2.5	17

#	Article	IF	Citations
109	Understanding the constitutive presentation of MHC class I immunopeptidomes in primary tissues. IScience, 2022, 25, 103768.	4.1	16
110	Antileukemia T-cell responses in CLL – We don't need no aberration. OncoImmunology, 2015, 4, e1011527.	4.6	15
111	Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer Journal, 2020, 10, 24.	6.2	15
112	In vitro effect of molluscan hemocyanins on CAL-29 and T-24 bladder cancer cell lines. Biomedical Reports, 2013, 1, 235-238.	2.0	14
113	The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek's disease virus peptides by using an unprecedented binding motif. PLoS Biology, 2021, 19, e3001057.	5.6	14
114	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	2.5	13
115	Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models. Journal of Experimental Medicine, 2020, 217, .	8.5	13
116	Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens. Cellular and Molecular Life Sciences, 2022, 79, 171.	5.4	13
117	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA–Peptide Multimer Staining Assay. Cytometry Part B - Clinical Cytometry, 2018, 94, 342-353.	1.5	12
118	Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome. Immunogenetics, 2019, 71, 203-216.	2.4	12
119	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. Oncotarget, 2017, 8, 43915-43924.	1.8	12
120	Peptides Made to Order. Immunity, 2006, 25, 693-695.	14.3	11
121	Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols. Annals of Surgical Oncology, 2017, 24, 1650-1657.	1.5	11
122	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11
123	SARS–CoV–2–reactive T–cell receptors isolated from convalescent COVID–19 patients confer potent T–cell effector function. European Journal of Immunology, 2021, 51, 2651-2664.	2.9	9
124	Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 613597.	4.8	8
125	Self Tolerance of Natural MHC Class I Ligands. International Reviews of Immunology, 1993, 10, 291-300.	3.3	7
126	Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8 [+] cytotoxic T cells. Haematologica, 2017, 102, e460-e464.	3.5	7

#	Article	IF	Citations
127	Argyrin F Treatment‐Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. Advanced Therapeutics, 2021, 4, 2100078.	3.2	7
128	In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 2000, 30, 1-7.	2.9	7
129	HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.. Journal of Clinical Oncology, 2018, 36, TPS3135-TPS3135.	1.6	7
130	MHC Class I-Restricted Antigen Processing â€" Lessons from Natural Ligands. Chemical Immunology and Allergy, 1993, 57, 113-133.	1.7	6
131	A Recombinant Bispecific CD20Ã—CD95 Antibody With Superior Activity Against Normal and Malignant B-cells. Molecular Therapy, 2016, 24, 298-305.	8.2	6
132	Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia. Blood, 2012, 120, 581-581.	1.4	6
133	Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model. Cancers, 2022, 14, 1158.	3.7	6
134	First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. BMC Medical Genetics, 2018, 19, 144.	2.1	5
135	Integrin Activation Enables Sensitive Detection of Functional CD4+ and CD8+ T Cells: Application to Characterize SARS-CoV-2 Immunity. Frontiers in Immunology, 2021, 12, 626308.	4.8	5
136	The Impact of Biomaterial Cell Contact on the Immunopeptidome. Frontiers in Bioengineering and Biotechnology, 2020, 8, 571294.	4.1	5
137	HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. Cancers, 2022, 14, 2260.	3.7	5
138	A Simple and Rapid Method for Quality Control of Major Histocompatibility Complexâ€"Peptide Monomers by Flow Cytometry. Frontiers in Immunology, 2017, 8, 96.	4.8	4
139	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leukemia and Lymphoma, 2018, 59, 1949-1958.	1.3	4
140	The administration route of tumor-antigen-specific T-helper cells differentially modulates the tumor microenvironment and senescence. Carcinogenesis, 2019, 40, 289-302.	2.8	4
141	Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. OncoImmunology, 2021, 10, 2006893.	4.6	4
142	Mass spectrometry for quality control of bispecific antibodies after SDSâ€PAGE inâ€gel digestion. Biotechnology and Bioengineering, 2021, 118, 3069-3075.	3.3	3
143	Abstract CT258: Interim safety and immunogenicity results of a phase I trial evaluating the multi-peptide COVID-19 vaccine candidate CoVac-1 for induction of SARS-CoV-2 T cell immunity in cancer patients with disease- or treatment-related immunoglobulin deficiency. Cancer Research, 2022, 82, CT258-CT258.	0.9	3
144	Molecular cloning of a macrophage-derived, interferon-inducible secreted immunoglobulin-binding protein. European Journal of Immunology, 1999, 29, 1504-1512.	2.9	2

#	Article	IF	Citations
145	Broad and Efficient Activation of Memory CD4+ T Cells by Novel HAdV- and HCMV-Derived Peptide Pools. Frontiers in Immunology, 2021, 12, 700438.	4.8	2
146	In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, 30, 1.		2
147	In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. , 2000, 30, 1.		2
148	Chromatin-activated neutrophils represent a major source of interferon Â. Annals of the Rheumatic Diseases, 2011, 70, A38-A39.	0.9	1
149	Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome. Leukemia and Lymphoma, 2021, 62, 1907-1919.	1.3	1
150	Abstract B124: Personalized peptide vaccination based on patient-individual tumor-specific variants induces T-cell responses in pediatric patients. Cancer Immunology Research, 2019, 7, B124-B124.	3.4	1
151	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. Journal of Clinical Oncology, 2020, 38, 3128-3128.	1.6	1
152	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)â€"Towards Peptide Based Immunotherapy. Blood, 2014, 124, 4518-4518.	1.4	1
153	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches. Blood, 2016, 128, 4232-4232.	1.4	1
154	Peptides presented by HLA molecules and clinical applications. Biochemical Society Transactions, 2000, 28, A119-A119.	3.4	0
155	TLR9-independent and immune complex-independent interferon Î± production by neutrophils upon netosis in response to circulating chromatin. Annals of the Rheumatic Diseases, 2012, 71, A84.1-A84.	0.9	0
156	IMMU-28. DECIPHERING THE AT/RT LIGANDOME. Neuro-Oncology, 2018, 20, i104-i104.	1.2	0
157	An Immunogenic Peptide Derived from NM23-H2 Is Expressed on Bcr/abl+ Cells.. Blood, 2006, 108, 3684-3684.	1.4	0
158	Inhibition of Antibody Production in Vitro with Bispecific CD20 X CD95 Antibodies. Blood, 2011, 118, 1114-1114.	1.4	0
159	Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis â€" New Targets for Peptide Based Immunotherapy. Blood, 2012, 120, 4119-4119.	1.4	0
160	Human Peripheral CD34+ Î³Î´ T Cells Can Transdifferentiate into Î±Î² T Cells.. Blood, 2012, 120, 2312-2312.	1.4	0
161	HLA Ligandome Analysis of Acute Myeloid Leukemia (AML) Revealed Novel Tumor-Associated Antigens for Immunotherapy.. Blood, 2012, 120, 3012-3012.	1.4	0
162	Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.. Blood, 2012, 120, 3060-3060.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. Blood, 2015, 126, 1722-1722.	1.4	0
164	Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules. Blood, 2018, 132, 5223-5223.	1.4	0
165	Identification of tumor antigens for T-cell-mediated cancer immunotherapy. , 2022, , 85-96.		0
166	Abstract 3555: Immunopeptidomics-guided tumor antigen warehouse design for peptide-based immunotherapy in head and neck squamous cell carcinomas. Cancer Research, 2022, 82, 3555-3555.	0.9	0